Raúl Insa, MD, PhD, MBA
Founder, President and CEO
Dr. Insa has worked for more than 20 years in multinational pharmaceutical companies such as Parke-Davis (now Pfizer), UCB Pharma, Uriach Group (now Palau Pharma) and ISDIN (from Esteve Group), before establishing SOM Biotech. His experience is in drug development, from drug identification to commercialization, including clinical research and licensing. He was involved in the development of products like Quinapril, Tacrine, Cetirizin, Levetiracetam, Rupatadin, Dersalazine, Cimicoxib, Albaconazole, Gemfibrozil, Gabapentin, Piracetam, Levocetirizine, Nanocapsuled Cyclosporin, Disitertide, and others. He received his Medical training and his PhD in Clinical Neurology from the University of Alicante, Spain; an MBA from ESADE Business School in Barcelona and an Executive Education Program from IESE, Barcelona. He has also attended a couple of biotech leadership programs at Harvard Business School, Boston. His background includes more than 45 publications and papers, 7 chapters in books, 87 congress communications and 9 pharmaceutical patents.
Martí Dalmases, MD, PhD, MBA
Martí is a Medical Doctor with PhD and MBA degrees. He has fostered, led and managed research and innovation projects, both public and private. He is an entrepreneur who is participating in the foundation of different startup companies and is collaborating with tech transfer offices from different sectors. Martí is the CEO of Nanosel (cancer drug delivery vehicle) SL, and Ahead Therapeutics SL (auto-immune disorders treatment).
Alberto Stampa, PhD
Alberto is a chemist and a pharmaceutical industry expert. He is the founder of Medichem (API manufacturer) and Combino Pharm (generics company).
Antoni Salgado, BSc
Antoni is a pharmacist and a regulatory expert. He has worked for companies such as Uriach, UCB, Lundbeck and Sobi.
Marc Sabé, BA
Marc has a large investment experience in technological companies, including the biotech industry.
Cleops SRL is an Italian private investment fund experienced in the biomedical sector.
Joaquim Trias, PhD
Scientific Advisory Board
Joaquim has more than 25 years of experience in contributing to multiple successful biotech startups, 3 approved drugs, 2 drugs brought to Phase 3 & 4, IPOs and 2 M&As.
Leonard Brandt, BA, MBA
Strategic Advisory Board
Leonard is an ex-general partner at Norwest Ventures and a co-founder of CNS Response Inc, Mill City Venture Consulting Inc, HDI, Empro Vascular and others.